TKNO Q2 2023 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$12M-1.4% YoY

Gross Profit

$5M43.9% margin

Operating Income

-$7M-60.7% margin

Net Income

-$7M-62.1% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+26.4%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$133M

Total Liabilities

$46M

Stockholders' Equity

$86M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$12M	-1.4%
Gross Profit	$5M	$5M	-3.4%
Operating Income	-$7M	-$7M	-5.6%
Net Income	-$7M	-$6M	-15.3%

Revenue Segments

Lab Essentials

$8M66%

Clinical Solutions

$4M32%

Other Product

$293,0003%

Geographic Segments

UNITED STATES

$11M96%

Non-US

$452,0004%